Le Lézard
Classified in: Health, Covid-19 virus
Subjects: TRI, FDA

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients


ST. PETERSBURG, Fla., June 23, 2021 /PRNewswire/ -- Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced that the US Food and Drug Administration has approved a New Investigational Drug application for RSLV-132 to initiate a phase 2 clinical trial in patients with long covid.

It is estimated that up to 30% of patients infected with SARS-CoV-2, the virus that causes COVID-19, have ongoing, debilitating symptoms lasting several months up to one year following the acute phase of the infection. The most common symptom by far is severe, debilitating fatigue. In addition, some patients appear to have an autoimmune component to their infection as several studies have observed the development of various autoantibodies following infection. Recent studies suggest that viral RNA and RNA-containing autoantibodies in the CNS of patients with long covid may be causing inflammation resulting in fatigue and brain fog. "Based on our previous positive phase 2 clinical trial with RSLV-132 in autoimmune fatigue, we are hopeful that removing circulating RNA in long covid patients will have a similar improvement in their fatigue and brain fog," said Dr. James Posada, chief executive officer of Resolve Therapeutics.

About RSLV-132

RSLV-132 is a safe, novel, targeted biologic drug designed to remove pro-inflammatory nucleic acids from the circulation of patients, which is one of the key triggers of multiple pro-inflammatory cascades. The compound consists of a catalytically active human RNase moiety fused to a human IgG1 Fc domain that digests RNA circulating in the blood and thereby decreases inflammation.

About Resolve Therapeutics

Resolve Therapeutics is pioneering safe, targeted therapies for underserved autoimmune diseases with large unmet medical needs. The Company's lead compound, RSLV-132, is a first-in-class investigational treatment in development for lupus and Sjogren's syndrome. The drug eliminates the inflammatory material found in the blood of patients with autoimmune diseases, thereby preventing the activation of numerous pro-inflammatory cascades. RSLV-132 removes just the inflammatory stimulating molecules, without shutting down the immune system or interfering with key steps in the innate immune system. For more information, visit http://resolvetherapeutics.com/.

Contacts:
James Posada
Resolve Therapeutics
208-727-7010
jp@resolvebio.com

Related Images

image1.jpg

SOURCE Resolve Therapeutics


These press releases may also interest you

at 16:20
In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple...

at 16:20
Ionis Pharmaceuticals, Inc. partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1...

at 15:30
Triumph and disaster so close together! Monster Energy congratulates Tom Van Steenbergen on taking first place in Best Trick at the 2021 Red Bull Rampage mountain bike competition this weekend. In the invite-only event inside Zion National Park,...

at 13:13
The Gas Turbines market will register an incremental spend of about USD 2.78 Billion, growing at a CAGR of 2.79% during the five-year forecast period. A targeted strategic approach to Gas Turbines sourcing can unlock several opportunities for buyers....

at 10:00
Dr. Milton C. Moreland was inaugurated as the 21st president of Centre College on Oct. 14 in an afternoon event held in Newlin Hall of the Norton Center for the Arts that focused on the theme, "Building a Community of Inclusive Excellence." The...

at 09:30
The Prime Minister, Justin Trudeau, today issued the following statement marking Small Business Week, which runs from October 17 to 23, 2021: "Small businesses are at the heart of our communities across the country. They are the small neighbourhood...



News published on 23 june 2021 at 09:00 and distributed by: